Verrica Pharmaceuticals Inc
VRCA
View Detailed Chart
4.690USD
+0.310+7.08%
Market hours （ET）Quotes delayed by 15 min
117.00MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+7.08%
5 Days
-13.94%
1 Month
-14.26%
6 Months
+9.07%
Year to Date
-43.56%
1 Year
+8.31%
View Detailed Chart
TradingKey Stock Score of Verrica Pharmaceuticals Inc
Currency: USD Updated: 2026-03-27Key Insights
Verrica Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 95 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 16.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Verrica Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Verrica Pharmaceuticals Inc Highlights
StrengthsRisks
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 594.32% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 35.58M.
Undervalued
The company’s latest PE is -2.61, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.04M shares, decreasing 13.99% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 138.19K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.95.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
16.500
Target Price
+275.85%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Verrica Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Verrica Pharmaceuticals Inc Info
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Ticker SymbolVRCA
CompanyVerrica Pharmaceuticals Inc
CEORieger (Jayson)
Websitehttps://verrica.com/
Related Instruments
-0.67%
-0.92%
+0.66%
+5.97%
-1.17%
+0.67%
+1.39%
-0.80%
-0.09%
+1.90%
-2.83%
+0.47%
+0.85%
+0.46%
-3.06%
0.00%
+0.21%
-0.80%
+2.39%
+1.16%Popular Symbols
247.180
-1.620 (-0.65%)
166.810
-0.710 (-0.42%)
67247.040
+662.990 (+1.00%)
254.790
-18.560 (-6.79%)
2061.150
+61.150 (+3.06%)
360.367
-1.463 (-0.40%)
4531.960
+39.440 (+0.88%)
102.552
+1.943 (+1.93%)
1.146
-0.004 (-0.38%)
159.465
-0.787 (-0.49%)
